Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 5/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112820 | 0.92 | ESR1 (0.64) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2112720 | 0.90 | ESR1 (0.66) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2112383 | 0.89 | ESR1 (0.59) | KDM4EESR1ESR2PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL2115234 | 0.86 | ESR1 (0.60) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2111205 | 0.86 | ESR1 (0.69) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2115656 | 0.86 | LTA4H (0.62) | KDM4EESR1ESR2PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL2113578 | 0.85 | ESR1 (0.68) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2112716 | 0.85 | LTA4H (0.64) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2112306 | 0.85 | ESR1 (0.62) | KDM4EESR1ESR2PSMB1PSMB5 | |
| SCHEMBL2112583 | 0.84 | ESR1 (0.57) | KDM4EESR1ESR2PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | KDM4E 3063/4885ESR1 7/4885ESR2 3/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | KDM4E 1462/4885ESR1 5/4885ESR2 3/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | KDM4E 1462/4885ESR1 5/4885ESR2 3/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | KDM4E 1462/4885ESR1 5/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.